Aquilo Capital Management
Latest statistics and disclosures from Aquilo Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ARWR, BPMC, KYMR, AMGN, ARVN, and represent 69.69% of Aquilo Capital Management's stock portfolio.
- Added to shares of these 8 stocks: AMGN (+$6.5M), PTGX, DTIL, BCYC, BPMC, RPTX, SLN, IMTX.
- Started 2 new stock positions in PTGX, AMGN.
- Reduced shares in these 7 stocks: , MRUS (-$5.9M), RGNX, STRO, ARVN, KYMR, ARWR.
- Sold out of its positions in SPY, MRUS.
- Aquilo Capital Management was a net seller of stock by $-45M.
- Aquilo Capital Management has $66M in assets under management (AUM), dropping by -49.71%.
- Central Index Key (CIK): 0001591986
Tip: Access up to 7 years of quarterly data
Positions held by Aquilo Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Aquilo Capital Management
Aquilo Capital Management holds 14 positions in its portfolio as reported in the December 2024 quarterly 13F filing
Company (Ticker) |
Portfolio Weight |
Valued At |
Change in Shares |
Share Count |
Share Price |
|
|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals (ARWR) | 22.2 | $15M | 783k | 18.80 |
|
|
| Blueprint Medicines (BPMC) | 17.0 | $11M | +4% | 130k | 87.22 |
|
| Kymera Therapeutics (KYMR) | 11.1 | $7.4M | -12% | 184k | 40.23 |
|
| Amgen Call Option (AMGN) | 9.8 | $6.5M | NEW | 25k | 260.64 |
|
| Arvinas Ord (ARVN) | 9.5 | $6.3M | -15% | 329k | 19.17 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 4.7 | $3.1M | +21% | 222k | 14.00 |
|
| Protagonist Therapeutics (PTGX) | 4.5 | $3.0M | NEW | 77k | 38.60 |
|
| Regenxbio Inc equity us cm (RGNX) | 4.0 | $2.7M | -62% | 346k | 7.73 |
|
| Immatics SHS (IMTX) | 4.0 | $2.7M | +12% | 374k | 7.11 |
|
| Silence Therapeutics Ads (SLN) | 3.8 | $2.5M | +15% | 367k | 6.88 |
|
| Adicet Bio (ACET) | 3.7 | $2.4M | 2.5M | 0.96 |
|
|
| Precision Biosciences Com New (DTIL) | 3.1 | $2.0M | +40% | 536k | 3.81 |
|
| Repare Therapeutics Ord (RPTX) | 2.6 | $1.7M | +30% | 1.3M | 1.31 |
|
| Sutro Biopharma (STRO) | 0.0 | $916.021200 | -99% | 498.00 | 1.84 |
|
Past Filings by Aquilo Capital Management
SEC 13F filings are viewable for Aquilo Capital Management going back to 2018
- Aquilo Capital Management 2024 Q4 filed Feb. 14, 2025
- Aquilo Capital Management 2024 Q3 filed Nov. 14, 2024
- Aquilo Capital Management 2024 Q2 filed Aug. 14, 2024
- Aquilo Capital Management 2024 Q1 filed May 15, 2024
- Aquilo Capital Management 2023 Q4 filed Feb. 14, 2024
- Aquilo Capital Management 2023 Q3 filed Nov. 14, 2023
- Aquilo Capital Management 2023 Q2 filed Aug. 14, 2023
- Aquilo Capital Management 2023 Q1 filed May 15, 2023
- Aquilo Capital Management 2022 Q4 filed Feb. 14, 2023
- Aquilo Capital Management 2022 Q3 filed Nov. 14, 2022
- Aquilo Capital Management 2022 Q2 filed Aug. 15, 2022
- Aquilo Capital Management 2022 Q1 filed May 16, 2022
- Aquilo Capital Management 2021 Q4 filed Feb. 14, 2022
- Aquilo Capital Management 2021 Q3 filed Nov. 15, 2021
- Aquilo Capital Management 2021 Q2 filed Aug. 16, 2021
- Aquilo Capital Management 2021 Q1 filed May 17, 2021